Women between ages 15 and 49 are typically eligible for contraceptive implants, as long as they meet certain health criteria ...

Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

There are three progestin-containing subdermal implants. The first implant to be developed was Norplant, which is no longer being manufactured. Norplant had six levonorgestrel-containing capsules ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

A woman in her late 30s presented with a complaint of not being able to palpate the subdermal contraceptive implant in her left arm, which was inserted 6 years earlier. An x-ray revealed a ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

Vivani’s lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...